Sanquin-LUMC Jon J. van Rood Center for Clinical Transfusion Research and the Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, the Netherlands.
Transfusion. 2013 May;53(5):939-47. doi: 10.1111/j.1537-2995.2012.03862.x. Epub 2012 Aug 23.
Women whose fetuses were treated with intrauterine transfusions (IUTs) for alloimmune hemolytic disease are high responders to red blood cell (RBC) antigens. We investigated the risk for HLA alloimmunization.
Women and their children treated with IUT between 1987 and 2008 were included. Participants were HLA antigen typed and studied for the prevalence of HLA antibodies compared to age-matched parous nontransfused blood donors. Anti-D titer, the formation of new RBC antibodies after IUT, and the degree of fetomaternal HLA mismatches on HLA antibody formation and/or persistence were analyzed.
A higher prevalence of HLA Class I antibodies was observed in these women compared to controls (41% vs. 23%). Both a higher anti-D titer (>8000) and formation of new RBC antibodies after IUT were associated with increased HLA immunization. HLA antibody formation was associated with the number of fetomaternal triplet epitope mismatches. Antigens within HLA-Bw4, HLA-B35/51/52/53/18/78-complex and A1/A9, were higher and mismatches within HLA-C were less immunogenic than expected. HLA antibodies against the IUT-treated fetus were more persistent than other antibodies.
Women whose fetuses were treated with IUT had a high risk of developing and maintain fetal-specific HLA Class I antibodies. Factors associated with increased HLA immunization were a higher amount of fetomaternal HLA triplet mismatches, higher anti-D titer, and additional RBC antibody formation. We presume that the induction of HLA Class I antibodies is the result of increased fetomaternal hemorrhage during IUT, eliciting antibodies in women with an increased susceptibility to alloimmunization.
胎儿接受宫内输血 (IUT) 治疗同种免疫性溶血性疾病的女性对红细胞 (RBC) 抗原高度反应。我们调查了 HLA 同种免疫的风险。
纳入 1987 年至 2008 年间接受 IUT 治疗的女性及其子女。对参与者进行 HLA 抗原分型,并与年龄匹配的非输血经产妇献血者进行 HLA 抗体流行率比较。分析 IUT 后抗-D 效价、新 RBC 抗体的形成以及胎儿与母体 HLA 错配程度对 HLA 抗体形成和/或持续存在的影响。
与对照组相比,这些女性 HLA I 类抗体的流行率更高(41% vs. 23%)。较高的抗-D 效价(>8000)和 IUT 后新 RBC 抗体的形成与 HLA 免疫增强相关。HLA 抗体的形成与胎儿与母体三肽错配的数量有关。HLA-Bw4、HLA-B35/51/52/53/18/78 复合物和 A1/A9 内的抗原以及 HLA-C 内的错配比预期的更具免疫原性。针对 IUT 治疗胎儿的 HLA 抗体比其他抗体更持久。
接受 IUT 治疗的胎儿的女性发生和维持胎儿特异性 HLA I 类抗体的风险很高。增加 HLA 免疫的相关因素包括更多的胎儿与母体 HLA 三肽错配、更高的抗-D 效价和额外的 RBC 抗体形成。我们推测,HLA I 类抗体的诱导是由于 IUT 期间胎儿与母体出血增加,使具有更高同种免疫易感性的女性产生抗体。